Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.

@article{Schneider2012LongtermAO,
  title={Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.},
  author={Tatiana C. Schneider and Randa M Abdulrahman and Eleonora P. M. Corssmit and Hans Morreau and Jan Smit and Ellen H. W. Kapiteijn},
  journal={European journal of endocrinology},
  year={2012},
  volume={167 5},
  pages={643-50}
}
OBJECTIVE We conducted a prospective phase II clinical trial to determine the efficacy of sorafenib in patients with advanced radio-iodine refractory differentiated thyroid cancer. In this article, the long-term results are presented. PATIENTS AND METHODS Thirty-one patients with progressive metastatic or locally advanced radioactive iodine refractory differentiated thyroid cancer received sorafenib 400 mg orally twice daily. The study end points included response rate, progression-free… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS
45 Citations
28 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 45 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 28 references

Reacquisition of RAI uptake in RAI - refractory metastatic thyroid cancers by pretreatment with the MEK inhibitor selumetinib

  • A LohHo, R Leboeuf, RK Grewal
  • Journal of Clinical Oncology
  • 2012

Anti-tumor Activity Observed in a Cohort of Patients (pts) with Differentiated Thyroid Cancer (DTC) in a Phase 1 Study of Cabozantinib (XL184)

  • ME Cabanillas, MS Brose, DA. Ramies
  • American Thyroid Association,
  • 2011

Similar Papers

Loading similar papers…